Functional cure of chronic hepatitis B (CHB)—or hepatitis B surface antigen (HBsAg) loss
after 24 weeks off therapy—is now the goal of treatment, but is rarely achieved with current …

Hepatitis B virus (HBV) is a non-cytopathic, hepatotropic virus with the potential to cause a
persistent infection, ultimately leading to cirrhosis and hepatocellular carcinoma. Over the …

Functional cure of hepatitis B is defined as sustained undetectable circulating HBsAg and
HBV DNA after a finite course of treatment. Barriers to HBV cure include the reservoirs for …

Accumulation of activated immune cells results in nonspecific hepatocyte killing in chronic
hepatitis B (CHB), leading to fibrosis and cirrhosis. This study aims to understand the …

Chronic HBV infection is a global public health burden estimated to impact nearly 300
million persons worldwide. Despite the advent of potent antiviral agents that effectively …

Background & Aims Chronic hepatitis B virus (HBV) infection is characterized by the
presence of defective viral envelope proteins (hepatitis B surface antigen [HBsAg]) and the …

Background & Aims Nucleos (t) ide analogues (NUCs) are the standard and mostly lifelong
treatment for chronic HBeAg-negative hepatitis B, as functional cure (loss of HBsAg) is rarely …

Hepatitis B virus (HBV)-specific CD8+ T cells play a dominant role during acute-resolving
HBV infection but are functionally impaired during chronic HBV infection in humans. These …

Fewer than 1% of chronic hepatitis B virus infections per year are cured with antiviral
treatment. This creates a need for long-term treatment, which poses challenges for patients …

Objective A hallmark of chronic HBV (cHBV) infection is the presence of impaired HBV-
specific CD8+ T cell responses. Functional T cell exhaustion induced by persistent antigen …